Robert Lakin

Robert Lakin

A journalist — both writer and editor — Robert has covered markets and economies for more than 20 years. His previous gigs include Bloomberg News, where he was emerging markets editor in Tel Aviv, McKinsey & Co. and McDonald & Company Investments, where he was equities research editor.

His deep experience includes covering startups, emerging markets, financial services, and capital markets.

He writes a Substack newsletter, TLV Strategist, which covers the Israel business scene.

Recent Articles

CLBS Stock: Why Caladrius Biosciences Is Soaring Today

Caladrius Biosciences is focused on treating coronary microvascular dysfunction. The condition is most common among women, especially after menopause.

DARE Stock: Why Daré Bioscience Is on the Move Today

Shares of Daré Bioscience look poised to double between yesterday and today. DARE stock is an investment in women's health niches.

GEVO Stock: Why Renewable Energy Play Gevo Is Climbing Higher Today

Gevo co-founder and Nobel chemistry laureate Frances Arnold was named co-chair of the President’s Council of Advisors on Science and Technology. Renewables are getting more attention as the Biden administration comes into office.

ZOM Stock: Why Zomedica Shares Are on the Move Again Today

Zomedica shares are surging after the company updated investors on a warrant-redemption cash influx and news that its end-of-March product rollout is on track. Pet-related stocks are hot and ZOM may be on the verge of a significant breakout.

Cannabis Stocks: 5 Reasons HEXO, MJ and APHA Stock Are on the Move Today

Cannabis stocks are active again on Thursday morning just a week before pot-friendly Democrats take power in Washington. HEXO, Aphria and a marijuana ETF are just a few of what's popping in pre-market.